Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  1996-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1161/01.ATV.16.6.763PMID 8640404
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects

  2004cited by this paper
• Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.

  1995cited by this paper
• Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids.

  1995cited by this paper
• Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia.

  1995cited by this paper
• Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia.

  1995cited by this paper
• Effects of ciprofibrate on LDL metabolism in man.

  1994cited by this paper
• A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apoB-containing lipoprotein subspecies. Identification of preferential cholesteryl ester acceptors in human plasma.

  1994cited by this paper
• Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.

  1994cited by this paper
• Comparative Efficacy and Safety of Micronized Fenofibrate and Simvastatin in Patients With Primary Type Ha or IIb Hyperlipidemia

  1994cited by this paper
• Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia.

  1994cited by this paper
• Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study.

  1994cited by this paper
• Heterogeneity of plasma low‐density lipoproteins and atherosclerosis risk

  1994cited by this paper
• Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk.

  1994cited by this paper
• Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects.

  1993cited by this paper
• Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia.

  1993cited by this paper
• Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects.

  1993cited by this paper
• Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.

  1993cited by this paper
• Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia.

  1993cited by this paper
• Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers.

  1993cited by this paper
• Fibric acid derivatives

  1992cited by this paper
• Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences.

  1992cited by this paper
• Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and alpha-fetoprotein as models.

  1992cited by this paper
• LDL particle size distribution. Results from the Framingham Offspring Study.

  1992cited by this paper
• Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor.

  1992cited by this paper
• Change in LDL particle size is associated with change in plasma triglyceride concentration.

  1992cited by this paper
• Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects.

  1991cited by this paper
• Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia.

  1991cited by this paper
• Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables.

  1991cited by this paper
• Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor.

  1991cited by this paper
• Lipid lowering drugs.

  1990cited by this paper
• Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.

  1990cited by this paper
• Role of fibric acids in the management of hyperlipidemia

  1990cited by this paper
• Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

  1989cited by this paper
• Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation.

  1988cited by this paper
• Guinea pig low density lipoproteins: structural and metabolic heterogeneity.

  1988cited by this paper
• Structure and biochemical effects of fenofibrate.

  1987cited by this paper
• Abnormal regulation of LDL receptor activity and abnormal cellular metabolism of hypertriglyceridaemic low density lipoprotein: normalization with bezafibrate therapy

  1987cited by this paper
• Fibric acids: effects on lipids and lipoprotein metabolism.

  1987cited by this paper
• Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.

  1987cited by this paper
• Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia.

  1986cited by this paper
• Nondenaturing polyacrylamide gradient gel electrophoresis.

  1986cited by this paper
• Fenofibrate Reduces Low Density Lipoprotein Catabolism in Hypertriglyceridemic Subjects

  1985cited by this paper
• Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.

  1984cited by this paper
• A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum.

  1981cited by this paper
• Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia.

  1981cited by this paper
• Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects.

  1980cited by this paper
• Kinetic bases of the primar hperlipidaemias: studies of apolipoprotein B turnover in geneticall defined subjects

  1980cited by this paper
• Particle distribution of human serum high density lipoproteins.

  1977cited by this paper
• The Mechanism of Action of Clofibrate and Tetranicotinoylfructose (Bradilan) on the Kinetics of Plasma Free Fatty Acid and Triglyceride Transport in Type IV und Type V Hypertriglyceridaemia

  1974cited by this paper
• Mechanism of the hypolipemic effect of clofibrate in postabsorptive man.

  1973cited by this paper
• Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia.

  1973cited by this paper

• Modifications on lipid profile and high-density lipoprotein function related to treatment with tofacitinib in female patients with rheumatoid arthritis: Impact of previous therapy with biological agents.

  2025cites this paper
• Childhood Hypertriglyceridemia: Is It Time for a New Approach?

  2022cites this paper
• Baseline Insulin Resistance Is a Determinant of the Small, Dense Low-Density Lipoprotein Response to Diets Differing in Saturated Fat, Protein, and Carbohydrate Contents

  2021cites this paper
• Effect of Tocilizumab on LDL and HDL Characteristics in Patients with Rheumatoid Arthritis. An Observational Study

  2021cites this paper
• Fenofibrate promotes PPARα-targeted recovery of the intestinal epithelial barrier at the host-microbe interface in dogs with diabetes mellitus

  2021cites this paper
• Solubility and Bioavailability of Fenofibrate Nanoformulations

  2020cites this paper
• Fibrate pharmacogenomics: expanding past the genome.

  2020cites this paper
• Serum triglyceride and cholesterol concentrations and lipoprotein profiles in dogs with naturally occurring pancreatitis and healthy control dogs

  2020cites this paper
• Free cholesterol transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis underlies the U-shape relationship between HDL-cholesterol and cardiovascular disease

  2019cites this paper
• Glycosylation of human plasma lipoproteins reveals a high level of diversity, which directly impacts their functional properties.

  2019cites this paper
• Dose Effects of Ammonium Perfluorooctanoate on Lipoprotein Metabolism in APOE*3-Leiden.CETP Mice

  2019cites this paper
• A mathematical model to estimate cholesterylester transfer protein (CETP) triglycerides flux in human plasma

  2019cites this paper
• Distinct phospholipid and sphingolipid species are linked to altered HDL function in apolipoprotein A-I deficiency.

  2019cites this paper
• Specific Nuclear Magnetic Resonance Lipoprotein Subclass Profiles and Central Arterial Stiffness in Type 1 Diabetes Mellitus: A Case Control Study

  2019cites this paper
• Hypolipidemic treatment and target values of lipids

  2018cites this paper
• Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence

  2018cites this paper
• Molecular mechanisms, prevalence, and molecular methods for familial combined hyperlipidemia disease: A review

  2018cites this paper
• Interventions to Reduce Cardiovascular Risk in Children with Type 1 Diabetes.

  2017cites this paper
• Structure-function relationships in reconstituted HDL: Focus on antioxidative activity and cholesterol efflux capacity.

  2017cites this paper
• Enhancing the Solubility of Fenofibrate by Nanocrystal Formation and Encapsulation

  2017cites this paper
• The comparison of the therapeutic effect of fenofibrate and gemfibrozil on lipid profile in patients with type two diabetes

  2017cites this paper
• Poor glycemic control in type 2 diabetes enhances functional and compositional alterations of small, dense HDL3c.

  2017cites this paper
• Original Research Article Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME)-2: the study protocol for a multi-centre, randomised, placebo-controlled trial

  2016cites this paper
• Combined Dyslipidemia in Children and Adolescents

  2016cites this paper
• A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies

  2016cites this paper
• D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile

  2016cites this paper
• Management of Moderate Hypertriglyceridemia in Childhood and Adolescence

  2016cites this paper
• Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME)-2: the study protocol for a multi-centre, randomised, placebo-controlled trial

  2016cites this paper
• PCSK9: The functional relevance of fenofibrate–statin combination therapy to reduce residual cardiovascular risk

  2015cites this paper
• Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.

  2015cites this paper
• Combined dyslipidemia in childhood.

  2015cites this paper
• Hypoglycemic, lipid-lowering and metabolic regulation activities of metforminium decavanadate (H2Metf)3 [V10O28]·8H2O using hypercaloric-induced carbohydrate and lipid deregulation in Wistar rats as biological model.

  2015cites this paper
• Metabolic alterations, HFE gene mutations and atherogenic lipoprotein modifications in patients with primary iron overload.

  2015cites this paper
• BEYOND PEROXISOME: ABCD2 MODIFIES PPARα SIGNALING AND IDENTIFIES A SUBCLASS OF PEROXISOMES IN MOUSE ADIPOSE TISSUE

  2014influential citation
• Genetic Risk Scores Associated with Baseline Lipoprotein Subfraction Concentrations Do Not Associate with Their Responses to Fenofibrate

  2014cites this paper
• Original Research Paper PHARMACOGENETIC STUDY OF FENOFIBRATE IN TUNISIAN TYPE 2 DIABETIC PATIENTS "A PRELIMINARY STUDY"

  2014cites this paper
• PHARMACOGENETIC STUDY OF FENOFIBRATE IN TUNISIAN TYPE 2 DIABETIC PATIENTS “A PRELIMINARY STUDY”

  2014cites this paper
• Effects of serum lipoproteins on cyclosporine A cellular uptake and renal toxicity in vitro.

  2014cites this paper
• Improved plasma cholesterol efflux capacity from human macrophages in patients with hyperalphalipoproteinemia.

  2014cites this paper
• Confronting the residual cardiovascular risk beyond statins: the role of fibrates, omega-3 fatty acids, or niacin, in diabetic patients.

  2014cites this paper
• Defective functionality of HDL particles in familial apoA-I deficiency: relevance of alterations in HDL lipidome and proteome[S]

  2014cites this paper
• A review of paradoxical HDL-C responses to fenofibrate, illustrated by a case report.

  2014cites this paper
• Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: relevance of inflammation.

  2014cites this paper
• pharmacological mechanisms and clinical efficacy

  2013cites this paper
• Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.

  2013cites this paper
• Novel lipoprotein density profiling in healthy dogs of various breeds, healthy miniature schnauzers, and miniature schnauzers with hyperlipidemia

  2013cites this paper
• Small, Dense High-Density Lipoprotein-3 Particles Are Enriched in Negatively Charged Phospholipids: Relevance to Cellular Cholesterol Efflux, Antioxidative, Antithrombotic, Anti-Inflammatory, and Antiapoptotic Functionalities

  2013cites this paper
• Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies

  2013cites this paper
• Functional activities of HDL particles in acute myocardial infarction : dissection of the roles of proteome vs. lipidome components

  2013cites this paper
• An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes

  2013cites this paper
• Investigations into hyperlipidemia and its possible associations with pancreatitis in dogs

  2012cites this paper
• Reverse cholesterol transport in familial hypercholesterolemia

  2012cites this paper
• Elevated Proportion of Small, Dense Low-Density Lipoprotein Particles and Lower Adiponectin Blood Levels Predict Early Structural Valve Degeneration of Bioprostheses

  2012cites this paper
• Lipid Profile as Early Predictor of Complication in Diabetes Mellitus

  2012cites this paper
• Variants Identified in a GWAS Meta-Analysis for Blood Lipids Are Associated with the Lipid Response to Fenofibrate

  2012cites this paper
• Micronised Fenofibrate

  2012cites this paper
• Fenofibrate

  2012cites this paper
• Fenofibrate

  2011cites this paper
• Fenofibrate

  2011cites this paper
• Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

  2011cites this paper
• LDL-apheresis depletes apoE-HDL and pre-β1-HDL in familial hypercholesterolemia: relevance to atheroprotection

  2011cites this paper
• Management of dyslipidemia in patients with diabetes

  2011cites this paper
• Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability.

  2011cites this paper
• HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events.

  2011cites this paper
• "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses.

  2011cites this paper
• Structural and biophysical insight into cholesteryl ester-transfer protein.

  2011cites this paper
• Advanced Lipid Testing

  2011cites this paper
• Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.

  2010cites this paper
• Selective CETP Inhibition and PPARα Agonism Increase HDL Cholesterol and Reduce LDL Cholesterol in Human ApoB100/Human CETP Transgenic Mice

  2010cites this paper
• Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia.

  2010cites this paper
• Do FADS genotypes enhance our knowledge about fatty acid related phenotypes?

  2010cites this paper
• Fenofibrate Increases Very Low Density Lipoprotein Triglyceride Production Despite Reducing Plasma Triglyceride Levels in APOE*3-Leiden.CETP Mice*

  2010cites this paper
• Plasma cholesteryl ester transfer protein (CETP) in relation to human pathophysiology

  2010cites this paper
• Modulation of VLDL triglyceride metabolism

  2010cites this paper
• Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting

  2010cites this paper
• High-density lipoprotein and coronary heart disease: current and future therapies.

  2010cites this paper
• Paradoxical decrease in high-density lipoprotein cholesterol with fenofibrate: a quite rare phenomenon indeed.

  2010cites this paper
• A NON-TZD PPARα/γ DUAL AGONIST CG301360 ALLEVIATES INSULIN RESISTANCE AND LIPID DYSREGULATION IN db/db MICE

  2010cites this paper
• Fenofibrate in the treatment of dyslipidemia associated with HIV infection

  2010cites this paper
• A Nonthiazolidinedione Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist CG301360 Alleviates Insulin Resistance and Lipid Dysregulation in db/db Mice

  2010cites this paper
• Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid

  2010cites this paper
• Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid

  2010cites this paper
• Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study[S]

  2010cites this paper
• Molecular pathways and agents for lowering LDL-cholesterol in addition to statins.

  2010cites this paper
• Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster

  2010cites this paper
• Genome-Wide Association Study of Plasma Polyunsaturated Fatty Acids in the InCHIANTI Study

  2009cites this paper
• Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study.

  2009cites this paper
• Pleiotropic effects of fenofibrate.

  2009cites this paper
• Lipids in Health and Disease

  2009cites this paper
• The puzzle of high-density lipoprotein in cardiovascular prevention

  2009cites this paper
• Cholesterol ester transfer protein (CETP), postprandial lipemia and hypolipidemic drugs.

  2009cites this paper
• Fibrates and microvascular complications in diabetes--insight from the FIELD study.

  2009cites this paper
• Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.

  2009cites this paper
• Pharmacotherapy of Mixed Hyperlipidemia with Ezetimibe–Fenofibrate Combination Therapy

  2009cites this paper
• CETP antagonism versus agonism in cardiovascular prevention and plaque regression

  2009cites this paper
• Familial hypercholesterolemia in childhood : diagnostics , therapeutical options and risk stratification

  2009cites this paper
• Torcetrapib Differentially Modulates the Biological Activities of HDL2 and HDL3 Particles in the Reverse Cholesterol Transport Pathway

  2009cites this paper
• Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

  2009cites this paper
• Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.

  2008cites this paper
• Treatment of hyperlipidaemia with fenofibrate and related fibrates.

  2008cites this paper